News: SDX Bard1 Life Sciences And Sienna Cancer Diagnostics Announce Merger, page-5

SDX has been undervalued for years and the Directors and succession of CEO’s haven’t been able to get it moving or generate any liquidity. The Science they have is good and a lot of present and future potential. BD1 have to set up on the East Coast So with this deal they avoid millions in cost , get the cash from SDX recent capital raise and broaden their immediate and future pipeline.
The SDX price is lousy and a market cap of only $10 million but that’s with about $7 million in cash and 2 great pieces of science and a ready made East Coast facility.
Great for both companies, watch this baby fly.